Hematology & Blood Cancer
Advertisement
A case series demonstrated the effectiveness of a novel trio for pediatric plasmacytic PTLD.
Adolescents and young adults face different challenges than older survivors of ALL. Can technology improve these challenges?
Prognostic understanding is essential to medical decision-making, but are these patients' hopes too high?
Accreditation and certification surveys validate an organization's quality of care. How can your organization be prepared?
Interprofessional team-based care is the standard for patients undergoing HSCT. But who belongs on the team?
Care teams at Thomas Jefferson University Hospital decreased time to chemotherapy administration by using new strategies.
ICANS, a complication of CAR T cell therapy, was associated with an injury that is detectable with a blood test.
The tablet form of blood cancer drug acalabrutinib has been FDA approved, making administration easier for certain patients.
One concern that keeps patients from enrolling in clinical trials is the belief that their quality of life will suffer.
Patients who receive a transplant at a young age may experience GVHD symptoms decades later, like oral chronic GVHD.
Anti-thymocyte globulin (ATG) is used in conditioning prior to allogeneic hematopoietic stem cell transplantation for acute ...
Pivotal trials that supported FDA approval of CAR T-cell therapies had low proportions of Black patients enrolled.
These findings were presented at the 2021 American Society of Hematology Annual Meeting.
Polatuzumab Vetodin Plus R-CHP Reduces Risk of Disease Progression or Death in Newly Diagnosed DLBCL
Hervé Tilly, MD, of Centre Henri Becquerel and University of Rouen in France, presented the new research at ASH 2021.
This lack of benefit was seen in the entire study population.
eripheral blood cytopenias may be associated with a higher risk of cancer-related mortality, particularly in Black patients.
This is according to preliminary data from a nonrandomized arm of the SEQUOIA trial.
The CAR T-cell therapy significantly improved event-free survival (EFS) compared with standard of care in patients with LBCL.
According to new research, circulating tumor DNA (ctDNA) accurately reflects tumor burden.
Investigator L. Elizabeth Budde, MD, PhD, presented the research at the 2021 ASH Annual Meeting.
Advertisement
670 Madison Ave.
Manalapan, NJ 07726